Anterior|Próximo

Impacto do direcionamento do fator ativador de plaquetas e seu receptor no tratamento do câncer

  • role： First author第一作者
  • Affiliation：

    Department of Molecular and Cell Biology, College of Life Sciences, University of Leicester, University Road, Leicester LE1 7RH, UK

Kimya Qaderi1,  
  • Affiliation：

    Department of Laboratory Medicine, Faculty of Paramedical, Kurdistan University of Medical Sciences, Sanandaj 66177-13446, Kurdistan, Iran

Arvin Shahmoradi2,  
  • Affiliation：

    Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, USA

Anita Thyagarajan3,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, USA

  • Email：ravi.sahu@wright.edu
  • Introduction：* Ravi P. Sahu ravi.sahu@wright.edu
Ravi P. Sahu3*

Resumo

O mediador lipídico fator ativador de plaquetas (PAF) e sua via de sinalização do receptor (PAFR) desempenham papéis críticos em uma ampla gama de condições fisiológicas e patofisiológicas, incluindo crescimento e metástase do câncer. A capacidade do PAFR de interagir com outras cascatas de sinalização oncogênicas faz dele um alvo promissor para o tratamento do câncer. Além disso, numerosos compostos naturais e sintéticos, caracterizados por diversas atividades farmacológicas como efeitos anti-inflamatórios e antitumorais, têm sido explorados por seu potencial como antagonistas de PAF e PAFR. Nesta revisão, fornecemos evidências abrangentes sobre a via de sinalização PAF/PAFR, destacando a eficácia de várias classes de inibidores e antagonistas de PAF e PAFR em vários modelos de câncer. Notavelmente, também são discutidos os efeitos sinérgicos dos antagonistas de PAF e PAFR na melhoria da eficácia da quimioterapia e da radioterapia em vários modelos experimentais de câncer. No geral, a síntese da revisão da literatura indica que visar o eixo PAF/PAFR representa uma abordagem promissora para o tratamento do câncer e também exerce sinergia com a quimioterapia e a radioterapia.

Palavras-chave

Fator ativador de plaquetas (PAF);Receptor do fator ativador de plaquetas (PAFR);Antagonistas;Inibidores;Câncer;Vias de sinalização celular;Radioterapia;Quimioterapia

References

  1. 1..
    Choi JW,Hua TNM. Impact of lifestyle behaviors on cancer risk and prevention. J Lifestyle Med. 2021;11(1):1-7.
  2. 2..
    Siegel RL,Giaquinto AN,Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
  3. 3..
    Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Q. 2005;83(4):731-57.
  4. 4..
    Weiderpass E. Lifestyle and cancer risk. J Prev Med Public Health.2010;43(6):459-71.
  5. 5..
    Khan FA,Akhtar SS,Sheikh MK. Cancer treatment: objectives and quality of life issues. Malays J Med Sci. 2005;12(1):3-5.
  6. 6..
    Galmarini CM. Why we do what we do. A brief analysis of cancer therapies. EXCLI J. 2020;19:1401-13.
  7. 7..
    Shuel SL. Targeted cancer therapies: clinical pearls for primary care. Can Fam Phys. 2022;68(7):515-8.
  8. 8..
    McAleer S. A history of cancer and its treatment: presidential address to the ulster medical society. 7th October 2021. Ulster Med J.2022;91(3):124-9.
  9. 9..
    Amjad MT,Chidharla A,Kasi A. Cancer Chemotherapy. StatPearls. Treasure Island (FL): StatPearls Publishin; 2024.
  10. 10..
    Joo WD,Visintin I,Mor G. Targeted cancer therapy-are the days of systemic chemotherapy numbered? Maturitas. 2013;76(4):308-14.
  11. 11..
    Travers JB,Rohan JG,Sahu RP. New insights into the pathologic roles of the platelet-activating factor system. Front Endocrinol. 2021;12:624132.
  12. 12..
    Braquet P,Touqui L,Shen TY,Vargaftig BB. Perspectives in plateletactivating factor research. Pharmacol Rev. 1987;39(2):97-145.
  13. 13..
    Ishii S,Nagase T,Shimizu T. Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat. 2002;68-69:599-609.
  14. 14..
    Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123-50.
  15. 15..
    Yost CC,Weyrich AS,Zimmerman GA. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie.2010;92(6):692-7.
  16. 16..
    Stafforini DM,McIntyre TM,Zimmerman GA,Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003;40(6):643-72.
  17. 17..
    Vadas P,Gold M,Perelman B,Liss GM,Lack G,Blyth T, et al. Plateletactivating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008;358(1):28-35.
  18. 18..
    Travers JB,Huff JC,Rola-Pleszczynski M,Gelfand EW,Morelli JG,Murphy RC. Identification of functional platelet-activating factor receptors on human keratinocytes. J Invest Dermatol. 1995;105(6):816-23.
  19. 19..
    Cellai C,Laurenzana A,Vannucchi AM,Caporale R,Paglierani M,Di Lollo S, et al. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br J Cancer.2006;94(11):1637-42.
  20. 20..
    Xu B,Gao L,Wang L,Tang G,He M,Yu Y, et al. Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. Br J Cancer. 2013;109(5):1279-86.
  21. 21..
    Biancone L,Cantaluppi V,Del Sorbo L,Russo S,Tjoelker LW,Camussi G. Platelet-activating factor inactivation by local expression of plateletactivating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res. 2003;9(11):4214-20.
  22. 22..
    Hyland IK,O’Toole RF,Smith JA,Bissember AC. Progress in the development of platelet-activating factor receptor (PAFr) antagonists and applications in the treatment of inflammatory diseases. ChemMedChem.2018;13(18):1873-84.
  23. 23..
    da Silva IA,Chammas R,Lepique AP,Jancar S. Platelet-activating factor(PAF) receptor as a promising target for cancer cell repopulation after radiotherapy. Oncogenesis. 2017;6(1): e296.
  24. 24..
    da Silva-Junior IA,Dalmaso B,Herbster S,Lepique AP,Jancar S. Plateletactivating factor receptor ligands protect tumor cells from radiation-induced cell death. Front Oncol. 2018;8:10.
  25. 25..
    da Silva Junior IA,de Sousa Andrade LN,Jancar S,Chammas R. Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy. Clinics. 2018;73(suppl 1):e792s.
  26. 26..
    Demopoulos CA,Pinckard RN,Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254(19):9355-8.
  27. 27..
    Prescott SM,Zimmerman GA,Stafforini DM,McIntyre TM. Plateletactivating factor and related lipid mediators. Annu Rev Biochem.2000;69:419-45.
  28. 28..
    Palur Ramakrishnan AV,Varghese TP,Vanapalli S,Nair NK,Mingate MD. Platelet activating factor: a potential biomarker in acute coronary syndrome? Cardiovasc Ther. 2017;35(1):64-70.
  29. 29..
    Reznichenko A,Korstanje R. The role of platelet-activating factor in mesangial pathophysiology. Am J Pathol. 2015;185(4):888-96.
  30. 30..
    Braquet P,Hosford D,Braquet M,Bourgain R,Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol. 1989;88(1-2):88-100.
  31. 31..
    Tsoupras A,Lordan R,Zabetakis I. Inflammation, not cholesterol, is a cause of chronic disease. Nutrients. 2018;10(5):604.
  32. 32..
    Lordan R,Tsoupras A,Zabetakis I,Demopoulos CA. Forty years since the structural elucidation of platelet-activating factor (PAF): historical, current, and future research perspectives. Molecules. 2019;24(23):4414.
  33. 33..
    Antonopoulou S,Nomikos T,Karantonis H,Fragopoulou E,Demopoulos C. PAF, a potent lipid mediator. Bioactive phospholipids. Role in inflammation and atherosclerosis. Kerala, India: transworld research network;2008.
  34. 34..
    Kulikov VI,Muzya GI. Ether lipids and platelet-activating factor: evolution and cellular function. Biochemistry (Mosc). 1997;62(10):1103-8.
  35. 35..
    McManus LM,Pinckard RN. PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med. 2000;11(2):240-58.
  36. 36..
    McManus LM,Woodard DS,Deavers SI,Pinckard RN. PAF molecular heterogeneity: pathobiological implications. Lab Invest. 1993;69(6):639-50.
  37. 37..
    Demopoulos CA,Antonopoulou S. A discovery trip to compounds with PAF-like activity. Adv Exp Med Biol. 1996;416:59-63.
  38. 38..
    Balestrieri ML,Castaldo D,Balestrieri C,Quagliuolo L,Giovane A,Servillo L. Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003;44(2):380-7.
  39. 39..
    Muñoz-Cano RM,Casas-Saucedo R,Valero Santiago A,Bobolea I,Ribó P,Mullol J. Platelet-activating factor (PAF) in allergic rhinitis: clinical and therapeutic implications. J Clin Med. 2019;8(9):1338.
  40. 40..
    Liu G,Kaneko M,Yoshioka K,Obara K,Tanaka Y. Platelet-activating factor (PAF) strongly enhances contractile mechanical activities in guinea pig and mouse urinary bladder. Sci Rep. 2022;12(1):2783.
  41. 41..
    Francescangeli E,Boila A,Goracci G. Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res.2000;25(5):705-13.
  42. 42..
    Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta.1995;1254(3):231-49.
  43. 43..
    Shindou H,Hishikawa D,Nakanishi H,Harayama T,Ishii S,Taguchi R, et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA: LYSO-PAF acetyltransferase. J Biol Chem.2007;282(9):6532-9.
  44. 44..
    Harayama T,Shindou H,Ogasawara R,Suwabe A,Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of plateletactivating factor. J Biol Chem. 2008;283(17):11097-106.
  45. 45..
    Nakanishi H,Shindou H,Hishikawa D,Harayama T,Ogasawara R,Suwabe A, et al. Cloning and characterization of mouse lung-type acyl-CoA: lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J Biol Chem. 2006;281(29):20140-7.
  46. 46..
    Chen X,Hyatt BA,Mucenski ML,Mason RJ,Shannon JM. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc Natl Acad Sci U S A. 2006;103(31):11724-9.
  47. 47..
    Harayama T,Shindou H,Shimizu T. Biosynthesis of phosphatidylcho-line by human lysophosphatidylcholine acyltransferase 1. J Lipid Res.2009;50(9):1824-31.
  48. 48..
    Shindou H,Shiraishi S,Tokuoka SM,Takahashi Y,Harayama T,Abe T, et al. Relief from neuropathic pain by blocking of the platelet-activating factor-pain loop. FASEB J. 2017;31(7):2973-80.
  49. 49..
    Valentine WJ,Yanagida K,Kawana H,Kono N,Noda NN,Aoki J, et al. Update and nomenclature proposal for mammalian lysophospholipid acyltransferases, which create membrane phospholipid diversity. J Biol Chem. 2022;298(1):101470.
  50. 50..
    Snyder F. CDP-choline: alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997;1348(1-2):111-6.
  51. 51..
    Tsoupras AB,Iatrou C,Frangia C,Demopoulos CA. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009;9(4):390-9.
  52. 52..
    Massey CV,Kohout TA,Gaa ST,Lederer WJ,Rogers TB. Molecular and cellular actions of platelet-activating factor in rat heart cells. J Clin Invest.1991;88(6):2106-16.
  53. 53..
    Shindou H,Ishii S,Uozumi N,Shimizu T. Roles of cytosolic phospholipase A2 and platelet-activating factor receptor in the Ca-induced biosynthesis of PAF. Biochem Biophys Res Commun. 2000;271(3):812-7.
  54. 54..
    Doebber TW,Wu MS. Platelet-activating factor (PAF) stimulates the PAF-synthesizing enzyme acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase and PAF synthesis in neutrophils. Proc Natl Acad Sci U S A. 1987;84(21):7557-61.
  55. 55..
    Lee T,Lenihan DJ,Malone B,Roddy LL,Wasserman SI. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984;259(9):5526-30.
  56. 56..
    Camussi G,Biancone L,Iorio EL,Silvestro L,Da Col R,Capasso C, et al. Porins and lipopolysaccharide stimulate platelet activating factor synthesis by human mesangial cells. Kidney Int. 1992;42(6):1309-18.
  57. 57..
    Svetlov SI,Liu H,Chao W,Olson MS. Regulation of platelet-activating factor (PAF) biosynthesis via coenzyme A-independent transacylase in the macrophage cell line IC-21 stimulated with lipopolysaccharide. Biochim Biophys Acta. 1997;1346(2):120-30.
  58. 58..
    Shindou H,Ishii S,Yamamoto M,Takeda K,Akira S,Shimizu T. Priming effect of lipopolysaccharide on acetyl-coenzyme A: lyso-plateletactivating factor acetyltransferase is MyD88 and TRIF independent. J Immunol. 2005;175(2):1177-83.
  59. 59..
    Wykle RL,Malone B,Snyder F. Enzymatic synthesis of 1-alkyl-2-acetylsn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem. 1980;255(21):10256-60.
  60. 60..
    Nieto ML,Velasco S,Sanchez CM. Modulation of acetyl-CoA:1-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PAF) acetyltransferase in human polymorphonuclears. The role of cyclic AMP-dependent and phospholipid sensitive, calcium-dependent protein kinases. J Biol Chem. 1988;263(10):4607-11.
  61. 61..
    Gómez-Cambronero J,Velasco S,Mato JM,Sánchez-Crespo M. Modulation of lyso-platelet activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of cyclic AMP-dependent protein kinase. Biochim Biophys Acta. 1985;845(3):516-9.
  62. 62..
    Gomez-Cambronero J,Mato JM,Vivanco F,Sanchez-Crespo M. Phosphorylation of partially purified 1-O-alkyl-2-lyso-sn-glycero-3-phos-phocholine: acetyl-CoA acetyltransferase from rat spleen. Biochem J.1987;245(3):893-7.
  63. 63..
    Morimoto R,Shindou H,Tarui M,Shimizu T. Rapid production of platelet-activating factor is induced by protein kinase Cα-mediated phosphorylation of lysophosphatidylcholine acyltransferase 2 protein. J Biol Chem. 2014;289(22):15566-76.
  64. 64..
    Morimoto R,Shindou H,Oda Y,Shimizu T. Phosphorylation of lysophosphatidylcholine acyltransferase 2 at Ser34 enhances platelet-activating factor production in endotoxin-stimulated macrophages. J Biol Chem.2010;285(39):29857-62.
  65. 65..
    Angle MJ,Tom R,Jarvi K,McClure RD. Effect of platelet-activating factor(PAF) on human spermatozoa-oocyte interactions. J Reprod Fertil.1993;98(2):541-8.
  66. 66..
    Sakellariou M,Drakakis P,Antonopoulou S,Anagnostou E,Loutradis D,Patargias T. Intravenous infusion of PAF affects ovulation, fertilization and preimplantation embryonic development in NZB x NZW F1 hybrid mice. Prostaglandins Other Lipid Mediat. 2008;85(3-4):125-33.
  67. 67..
    Lecewicz M,Kordan W,Majewska A,Kamiński S,Dziekońska A,Mietelska K. Effects of the platelet-activating factor (PAF) on selected quality parameters of cryopreserved bull semen (AI) with reduced sperm motility. Pol J Vet Sci. 2016;19(1):147-58.
  68. 68..
    Tiemann U. The role of platelet-activating factor in the mammalian female reproductive tract. Reprod Domest Anim. 2008;43(6):647-55.
  69. 69..
    Wu H,Gao J,Wang X,Leung TY,Duan YG,Chiu PCN. Platelet-activating factor induces acrosome reaction via the activation of extracellular signal-regulated kinase in human spermatozoa. Andrologia.2020;52(5):e13565.
  70. 70..
    Venable ME,Zimmerman GA,McIntyre TM,Prescott SM. Platelet-activating factor: a phospholipid autacoid with diverse actions. J Lipid Res.1993;34(5):691-702.
  71. 71..
    Damiani E,Ullrich SE. Understanding the connection between plateletactivating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer. Prog Lipid Res. 2016;63:14-27.
  72. 72..
    Mullol J,Bousquet J,Bachert C,Canonica WG,Gimenez-Arnau A,Kowalski ML, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy.2008;63(Suppl 87):5-28.
  73. 73..
    Kasperska-Zajac A,Brzoza Z,Rogala B. Platelet-activating factor (PAF):a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov.2008;2(1):72-6.
  74. 74..
    Winkler K,Abletshauser C,Hoffmann MM,Friedrich I,Baumstark MW,Wieland H, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus:baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 2002;87(12):5485-90.
  75. 75..
    Jancar S,Chammas R. PAF receptor and tumor growth. Curr Drug Targets. 2014;15(10):982-7.
  76. 76..
    Satoh K. Plasma platelet-activating factor acetylhydrolase (PAF-AH)deficiency as a risk factor for stroke. Brain Nerve. 2008;60(11):1319-24.
  77. 77..
    Ishii S,Kuwaki T,Nagase T,Maki K,Tashiro F,Sunaga S, et al. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med.1998;187(11):1779-88.
  78. 78..
    Kelesidis T,Papakonstantinou V,Detopoulou P,Fragopoulou E,Chini M,Lazanas MC, et al. The role of platelet-activating factor in chronic inflammation, immune activation, and comorbidities associated with HIV infection. AIDS Rev. 2015;17(4):191-201.
  79. 79..
    Theoharides TC,Antonopoulou S,Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin Ther.2020;42(10):1850-2.
  80. 80..
    Tsoupras A,Lordan R,Zabetakis I. Thrombosis and COVID-19: the potential role of nutrition. Front Nutr. 2020;7:583080.
  81. 81..
    Papakonstantinou VD,Lagopati N,Tsilibary EC,Demopoulos CA,Philippopoulos AI. A review on platelet activating factor inhibitors: could a new class of potent metal-based anti-inflammatory drugs induce anticancer properties? Bioinorg Chem Appl. 2017;2017:6947034.
  82. 82..
    Ishino T,Oda T,Kawasumi T,Takemoto K,Nishida M,Horibe Y, et al. Severe type 2 inflammation leads to high platelet-activating-factorassociated pathology in chronic rhinosinusitis with nasal polyps-a hierarchical cluster analysis using bulk RNA barcoding and sequencing. Int J Mol Sci. 2024;25(4):2113.
  83. 83..
    Yamamoto S,Hashidate-Yoshida T,Yoshinari Y,Shimizu T,Shindou H. Macrophage/microglia-producing transient increase of platelet-activating factor is involved in neuropathic pain. iScience. 2024;27(4):109466.
  84. 84..
    Kawano DF,Carvalho I. Targeting trypanosoma cruzi platelet-activating factor receptors: scope for the development of novel drugs to treat chagas disease. Mini Rev Med Chem. 2013;13(7):997-1004.
  85. 85..
    Honda Z,Ishii S,Shimizu T. Platelet-activating factor receptor. J Biochem. 2002;131(6):773-9.
  86. 86..
    Honda Z,Nakamura M,Miki I,Minami M,Watanabe T,Seyama Y, et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature. 1991;349(6307):342-6.
  87. 87..
    Upton JEM,Grunebaum E,Sussman G,Vadas P. Platelet activating factor(PAF): a mediator of inflammation. BioFactors. 2022;48(6):1189-202.
  88. 88..
    Kunz D,Gerard NP,Gerard C. The human leukocyte platelet-activating factor receptor. cDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. J Biol Chem. 1992;267(13):9101-6.
  89. 89..
    Chao W,Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J. 1993;292(Pt 3):617-29.
  90. 90..
    Dupré DJ,Le Gouill C,Rola-Pleszczynski M,Stanková J. Inverse agonist activity of selected ligands of platelet-activating factor receptor. J Pharmacol Exp Ther. 2001;299(1):358-65.
  91. 91..
    Cao C,Tan Q,Xu C,He L,Yang L,Zhou Y, et al. Structural basis for signal recognition and transduction by platelet-activating-factor receptor. Nat Struct Mol Biol. 2018;25(6):488-95.
  92. 92..
    Demopoulos CA,Karantonis HC,Antonopoulou S. Platelet activating factor: a molecular link between atherosclerosis theories. Eur J Lipid Sci Tech. 2003;105(11):705-16.
  93. 93..
    Kim KJ,Cho KD,Jang KY,Kim HA,Kim HK,Lee HK, et al. Platelet-activating factor enhances tumour metastasis via the reactive oxygen speciesdependent protein kinase casein kinase 2-mediated nuclear factor-κB activation. Immunology. 2014;143(1):21-32.
  94. 94..
    Salajegheh A. Platelet-activating factor angiogenesis in health, disease and malignancy. Cham: Springer; 2016.
  95. 95..
    Lordan R,Tsoupras A,Zabetakis I. Phospholipids of animal and marine origin: structure, function, and anti-inflammatory properties. Molecules.2017;22(11):1964.
  96. 96..
    Montrucchio G,Sapino A,Bussolati B,Ghisolfi G,Rizea-Savu S,Silvestro L, et al. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol. 1998;153(5):1589-96.
  97. 97..
    Im SY,Ko HM,Kim JW,Lee HK,Ha TY,Lee HB, et al. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res.1996;56(11):2662-5.
  98. 98..
    Camussi G,Montrucchio G,Lupia E,De Martino A,Perona L,Arese M, et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparindependent mechanism. J Immunol. 1995;154(12):6492-501.
  99. 99..
    Bussolati B,Russo S,Deambrosis I,Cantaluppi V,Volpe A,Ferrando U, et al. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int J Cancer. 2002;100(6):654-61.
  100. 100..
    Ishii S,Nagase T,Tashiro F,Ikuta K,Sato S,Waga I, et al. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J. 1997;16(1):133-42.
  101. 101..
    Biancone L,Cantaluppi V,Boccellino M,Bussolati B,Del Sorbo L,Conaldi PG, et al. Motility induced by human immunodeficiency virus-1 Tat on Kaposi’s sarcoma cells requires platelet-activating factor synthesis. Am J Pathol. 1999;155(5):1731-9.
  102. 102..
    Lohmeyer M,McNaughton L,Hunt SP,Workman P. Stimulation of intracellular free calcium increases by platelet-activating factor in HT29 colon carcinoma cells. Spectrofluorimetric and preliminary spatiotemporal analysis using confocal laser scanning fluorescence imaging microscopy. Biochem Pharmacol. 1994;47(6):975-85.
  103. 103..
    Diserbo M,Cand F,Ziade M,Verdetti J. Stimulation of platelet-activating factor (PAF) receptors increases inositol phosphate production and cytosolic free Ca2+ concentrations in N1E-115 neuroblastoma cells. Cell Calcium. 1995;17(6):442-52.
  104. 104..
    JrThurston AW,Rhee SG,Shukla SD. Role of guanine nucleotide-binding protein and tyrosine kinase in platelet-activating factor activation of phospholipase C in A431 cells: proposal for dual mechanisms. J Pharmacol Exp Ther. 1993;266(2):1106-12.
  105. 105..
    Mutoh H,Ishii S,Izumi T,Kato S,Shimizu T. Platelet-activating factor(PAF) positively auto-regulates the expression of human PAF receptor transcript 1 (leukocyte-type) through NF-kappa B. Biochem Biophys Res Commun. 1994;205(2):1137-42.
  106. 106..
    Bussolino F,Arese M,Montrucchio G,Barra L,Primo L,Benelli R, et al. Platelet activating factor produced in vitro by Kaposi’s sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest.1995;96(2):940-52.
  107. 107..
    Brizzi MF,Battaglia E,Montrucchio G,Dentelli P,Del Sorbo L,Garbarino G, et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res. 1999;84(7):785-96.
  108. 108..
    Montrucchio G,Lupia E,Battaglia E,Passerini G,Bussolino F,Emanuelli G, et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med.1994;180(1):377-82.
  109. 109..
    Fallani A,Grieco B,Barletta E,Mugnai G,Giorgi G,Salvini L, et al. Synthesis of platelet-activating factor (PAF) in transformed cell lines of a different origin. Prostaglandins Other Lipid Mediat. 2002;70(1-2):209-26.
  110. 110..
    Ji W,Chen J,Mi Y,Wang G,Xu X,Wang W. Platelet-activating factor receptor activation promotes prostate cancer cell growth, invasion and metastasis via ERK1/2 pathway. Int J Oncol. 2016;49(1):181-8.
  111. 111..
    Bussolati B,Biancone L,Cassoni P,Russo S,Rola-Pleszczynski M,Montrucchio G, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol. 2000;157(5):1713-25.
  112. 112..
    Lordan R,Tsoupras A,Zabetakis I. The potential role of dietary plateletactivating factor inhibitors in cancer prevention and treatment. Adv Nutr. 2019;10(1):148-64.
  113. 113..
    Angiogenesis in Health, Diseases and Malignancy. Anticancer Research.2016;36(6):3226.
  114. 114..
    Hou T,Lou Y,Li S,Zhao C,Ji Y,Wang D, et al. Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway. Oncol Lett.2018;16(2):2255-62.
  115. 115..
    Anandi VL,Ashiq KA,Nitheesh K,Lahiri M. Platelet-activating factor promotes motility in breast cancer cells and disrupts non-transformed breast acinar structures. Oncol Rep. 2016;35(1):179-88.
  116. 116..
    Gao T,Zhao R,Yao L,Xu C,Cong Q,Jiang W. Platelet-activating factor induces the stemness of ovarian cancer cells via the PAF/PAFR signaling pathway. Am J Transl Res. 2020;12(11):7249-61.
  117. 117..
    Gao T,Yu Y,Cong Q,Wang Y,Sun M,Yao L, et al. Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor. BMC Cancer.2018;18(1):999.
  118. 118..
    Yu Y,Zhang X,Hong S,Zhang M,Cai Q,Jiang W, et al. Epidermal growth factor induces platelet-activating factor production through receptors transactivation and cytosolic phospholipase A2 in ovarian cancer cells. J Ovarian Res. 2014;7:39.
  119. 119..
    Deuster E,Hysenaj I,Kahaly M,Schmoeckel E,Mayr D,Beyer S, et al. The platelet-activating factor receptor’s association with the outcome of ovarian cancer patients and its experimental inhibition by rupatadine. Cells. 2021;10(9):2337.
  120. 120..
    Chauhan SJ,Thyagarajan A,Sahu RP. Effects of miRNA-149-5p and platelet-activating factor-receptor signaling on the growth and targeted therapy response on lung cancer cells. Int J Mol Sci. 2022;23(12):6772.
  121. 121..
    Hackler PC,Reuss S,Konger RL,Travers JB,Sahu RP. Systemic plateletactivating factor receptor activation augments experimental lung tumor growth and metastasis. Cancer Growth Metastasis. 2014;7:27-32.
  122. 122..
    Chen J,Lan T,Zhang W,Dong L,Kang N,Zhang S, et al. Feed-forward reciprocal activation of PAFR and STAT3 regulates epithelialmesenchymal transition in non-small cell lung cancer. Cancer Res.2015;75(19):4198-210.
  123. 123..
    Puebla-Osorio N,Damiani E,Bover L,Ullrich SE. Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells. Cell Death Dis. 2015;6(5):e1745.
  124. 124..
    Chacón-Salinas R,Chen L,Chávez-Blanco AD,Limón-Flores AY,Ma Y,Ullrich SE. An essential role for platelet-activating factor in activating mast cell migration following ultraviolet irradiation. J Leukoc Biol.2014;95(1):139-48.
  125. 125..
    Shida-Sakazume T,Endo-Sakamoto Y,Unozawa M,Fukumoto C,Shimada K,Kasamatsu A, et al. Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor. PLoS One.2015;10(3):e0120143.
  126. 126..
    Zhao D,Zhang J,Zhang L,Wu Q,Wang Y,Zhang W, et al. PAFR/Stat3 axis maintains the symbiotic ecosystem between tumor and stroma to facilitate tumor malignancy. Acta Pharm Sin B. 2023;13(2):694-708.
  127. 127..
    Harbeck N,Gnant M. Breast cancer. Lancet. 2017;389(10074):1134-50.
  128. 128..
    Akram M,Iqbal M,Daniyal M,Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33.
  129. 129..
    Park M,Kim D,Ko S,Kim A,Mo K,Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci.2022;23(12):6806.
  130. 130..
    Shao H,Varamini P. Breast cancer bone metastasis: a narrative review of emerging targeted drug delivery systems. Cells. 2022;11(3):388.
  131. 131..
    Gerratana L,Fanotto V,Bonotto M,Bolzonello S,Minisini AM,Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32(2):125-33.
  132. 132..
    Pu CC,Yin L,Yan JM. Risk factors and survival prediction of young breast cancer patients with liver metastases: a population-based study. Front Endocrinol. 2023;14:1158759.
  133. 133..
    Zhang X,Miao J,Song Y,Zhang J,Miao M. Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis. Heliyon. 2024;10(18):e37894.
  134. 134..
    Zuo Q,Park NH,Lee JK,Madak EZ. Liver metastatic breast cancer: epidemiology, dietary interventions, and related metabolism. Nutrients.2022;14(12):2376.
  135. 135..
    Clarke MF,Dick JE,Dirks PB,Eaves CJ,Jamieson CH,Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res.2006;66(19):9339-44.
  136. 136..
    Nguyen LV,Vanner R,Dirks P,Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12(2):133-43.
  137. 137..
    Tang C,Ang BT,Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J. 2007;21(14):3777-85.
  138. 138..
    Phi LTH,Sari IN,Yang YG,Lee SH,Jun N,Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923.
  139. 139..
    Prieto-Vila M,Takahashi RU,Usuba W,Kohama I,Ochiya T. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci.2017;18(12):2574.
  140. 140..
    Karunanithi S,Levi L,DeVecchio J,Karagkounis G,Reizes O,Lathia JD, et al. RBP4-STRA6 pathway drives cancer stem cell maintenance and mediates high-fat diet-induced colon carcinogenesis. Stem Cell Rep.2017;9(2):438-50.
  141. 141..
    Chang WW,Lin RJ,Yu J,Chang WY,Fu CH,Lai A, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res.2013;15(3):R39.
  142. 142..
    Zhang L,Sun H,Zhao F,Lu P,Ge C,Li H, et al. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res.2012;72(16):4276-85.
  143. 143..
    Bosukonda A,Carlson WD. Harnessing the BMP signaling pathway to control the formation of cancer stem cells by effects on epithelial-to-mesenchymal transition. Biochem Soc Trans. 2017;45(1):223-8.
  144. 144..
    Rack B,Bock C,Andergassen U,Doisneau-Sixou S. Hormone receptor status, erbB2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients. Histol Histopathol.2012;27(7):855-64.
  145. 145..
    Jardé T,Kass L,Staples M,Lescesen H,Carne P,Oliva K, et al. ERBB3 positively correlates with intestinal stem cell markers but marks a distinct non proliferative cell population in colorectal cancer. PLoS One. 2015;10(9):e0138336.
  146. 146..
    Fan X,Gay FP,Lim FW,Ang JM,Chu PP,Bari S, et al. Low-dose insulin-like growth factor binding proteins 1 and 2 and angiopoietin-like protein 3 coordinately stimulate ex vivo expansion of human umbilical cord blood hematopoietic stem cells as assayed in NOD/SCID gamma null mice. Stem Cell Res Ther. 2014;5(3):71.
  147. 147..
    Zhao D,Pan C,Sun J,Gilbert C,Drews-Elger K,Azzam DJ, et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 2015;34(24):3107-19.
  148. 148..
    Sobrevals L,Mato-Berciano A,Urtasun N,Mazo A,Fillat C. uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors. Stem Cell Res. 2014;12(1):1-10.
  149. 149..
    Duhachek-Muggy S,Qi Y,Wise R,Alyahya L,Li H,Hodge J, et al. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Mol Cancer. 2017;16(1):32.
  150. 150..
    Sisay M,Mengistu G,Edessa D. The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther. 2017;10:3801-10.
  151. 151..
    Justilien V,Regala RP,Tseng IC,Walsh MP,Batra J,Radisky ES, et al. Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One.2012;7(4):e35040.
  152. 152..
    Aponte M,Jiang W,Lakkis M,Li MJ,Edwards D,Albitar L, et al. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res. 2008;68(14):5839-48.
  153. 153..
    Sahu RP,Ocana JA,Harrison KA,Ferracini M,Touloukian CE,Al-Hassani M, et al. Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res.2014;74(23):7069-78.
  154. 154..
    Sahu RP,Harrison KA,Weyerbacher J,Murphy RC,Konger RL,Garrett JE, et al. Radiation therapy generates platelet-activating factor agonists. Oncotarget. 2016;7(15):20788-800.
  155. 155..
    Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst. 1974;53(5):1333-6.
  156. 156..
    Fisher MS,Kripke ML. Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science.1982;216(4550):1133-4.
  157. 157..
    Walterscheid JP,Ullrich SE,Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med. 2002;195(2):171-9.
  158. 158..
    Wolf P,Nghiem DX,Walterscheid JP,Byrne S,Matsumura Y,Matsumura Y, et al. Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol. 2006;169(3):795-805.
  159. 159..
    Zhang Q,Yao Y,Konger RL,Sinn AL,Cai S,Pollok KE, et al. UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system. J Invest Dermatol. 2008;128(7):1780-7.
  160. 160..
    Marathe GK,Johnson C,Billings SD,Southall MD,Pei Y,Spandau D, et al. Ultraviolet B radiation generates platelet-activating factor-like phospholipids underlying cutaneous damage. J Biol Chem.2005;280(42):35448-57.
  161. 161..
    Alappatt C,Johnson CA,Clay KL,Travers JB. Acute keratinocyte damage stimulates platelet-activating factor production. Arch Dermatol Res. 2000;292(5):256-9.
  162. 162..
    Eller FJ,Taylor SL. Pressurized fluids for extraction of cedarwood oil from Juniperus virginianna. J Agric Food Chem. 2004;52(8):2335-8.
  163. 163..
    Chang KF,Chang JT,Huang XF,Huang YC,Li CY,Weng JC, et al. Cedrus atlantica extract suppress glioblastoma growth through promotion of genotoxicity and apoptosis: in vitro and in vivo studies. Int J Med Sci. 2021;18(11):2417-30.
  164. 164..
    Sakhaee MH,Sayyadi SAH,Sakhaee N,Sadeghnia HR,Hosseinzadeh H,Nourbakhsh F, et al. Cedrol protects against chronic constriction injury-induced neuropathic pain through inhibiting oxidative stress and inflammation. Metab Brain Dis. 2020;35(7):1119-26.
  165. 165..
    Jantan I,Rafi IA,Jalil J. Platelet-activating factor (PAF) receptor-binding antagonist activity of Malaysian medicinal plants. Phytomedicine.2005;12(1-2):88-92.
  166. 166..
    Oh I,Yang WY,Park J,Lee S,Mar W,Oh KB, et al. In vitro Na+/K+-ATPase inhibitory activity and antimicrobial activity of sesquiterpenes isolated from Thujopsis dolabrata. Arch Pharm Res.2011;34(12):2141-7.
  167. 167..
    Kagawa D,Jokura H,Ochiai R,Tokimitsu I,Tsubone H. The sedative effects and mechanism of action of cedrol inhalation with behavioral pharmacological evaluation. Planta Med. 2003;69(7):637-41.
  168. 168..
    Zhang Y,Han L,Chen SS,Guan J,Qu FZ,Zhao YQ. Hair growth promoting activity of cedrol isolated from the leaves of Platycladus orientalis. Biomed Pharmacother. 2016;83:641-7.
  169. 169..
    Yang HO,Suh DY,Han BH. Isolation and characterization of platelet-activating factor receptor binding antagonists from Biota orientalis. Planta Med. 1995;61(1):37-40.
  170. 170..
    Loizzo MR,Tundis R,Menichini F,Saab AM,Statti GA,Menichini F. Antiproliferative effects of essential oils and their major constituents in human renal adenocarcinoma and amelanotic melanoma cells. Cell Prolif. 2008;41(6):1002-12.
  171. 171..
    Huang SP,Lin LC,Wu YT,Tsai TH. Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system. J Chromatogr B Analyt Technol Biomed Life Sci.2009;877(3):247-52.
  172. 172..
    Zhang N,Li R,Yu H,Shi D,Dong N,Zhang S, et al. Development of an LC-MS/MS method for quantification of kadsurenone in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr.2013;27(12):1754-8.
  173. 173..
    Lee J,Kang U,Seo EK,Kim YS. Heme oxygenase-1-mediated anti-inflammatory effects of tussilagonone on macrophages and 12-O-tetra-decanoylphorbol-13-acetate-induced skin inflammation in mice. Int Immunopharmacol. 2016;34:155-64.
  174. 174..
    Hwangbo C,Lee HS,Park J,Choe J,Lee JH. The anti-inflammatory effect of tussilagone, from Tussilago farfara, is mediated by the induction of heme oxygenase-1 in murine macrophages. Int Immunopharmacol.2009;9(13-14):1578-84.
  175. 175..
    Lim HJ,Lee HS,Ryu JH. Suppression of inducible nitric oxide synthase and cyclooxygenase-2 expression by tussilagone from Farfarae flos in BV-2 microglial cells. Arch Pharm Res. 2008;31(5):645-52.
  176. 176..
    Kim YK,Yeo MG,Oh BK,Kim HY,Yang HJ,Cho SS, et al. Tussilagone inhibits the inflammatory response and improves survival in CLP-induced septic mice. Int J Mol Sci. 2017;18(12):2744.
  177. 177..
    Hwang SB,Chang MN,Garcia ML,Han QQ,Huang L,King VF, et al. L-652, 469-a dual receptor antagonist of platelet activating factor and dihydropyridines from Tussilago farfara L. Eur J Pharmacol.1987;141(2):269-81.
  178. 178..
    Morais LCS,Pachu CO,Santos VL,Barbosa-Filho TM. New lignan from Ocotea duckei. Fitoterapia. 1996. .
  179. 179..
    Morais LCSL,Almeida RN,da Cunha EVL,da Silva MS,Barbosa-Filho JM,Gray AI. Further lignans from Ocotea duckei. Pharm Biol.1999;37(2):144-7.
  180. 180..
    Marques RCP,de Medeiros SRB,Dias Cda S,Barbosa-Filho JM,Agnez-Lima LF. Evaluation of the mutagenic potential of yangambin and of the hydroalcoholic extract of Ocotea duckei by the Ames test. Mutat Res. 2003;536(1-2):117-20.
  181. 181..
    Castro-Faria-Neto HC,Bozza PT,Cruz HN,Silva CL,Violante FA,Barbosa-Filho JM, et al. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies. Planta Med. 1995;61(2):101-5.
  182. 182..
    Yeh KY,Shou SS,Lin YX,Chen CC,Chiang CY,Yeh CY. Effect of Ginkgo biloba extract on lipopolysaccharide-induced anhedonic depressive-like behavior in male rats. Phytother Res. 2015;29(2):260-6.
  183. 183..
    Ong SKL,Shanmugam MK,Fan L,Fraser SE,Arfuso F,Ahn KS, et al. Focus on formononetin: anticancer potential and molecular targets. Cancers.2019;11(5):611.
  184. 184..
    Gu JH,Ge JB,Li M,Wu F,Zhang W,Qin ZH. Inhibition of NF-κB activation is associated with anti-inflammatory and anti-apoptotic effects of Ginkgolide B in a mouse model of cerebral ischemia/reperfusion injury. Eur J Pharm Sci. 2012;47(4):652-60.
  185. 185..
    Zhao Q,Gao C,Cui Z. Ginkgolide A reduces inflammatory response in high-glucose-stimulated human umbilical vein endothelial cells through STAT3-mediated pathway. Int Immunopharmacol.2015;25(2):242-8.
  186. 186..
    Zhang S,Chen B,Wu W,Bao L,Qi R. Ginkgolide B reduces inflammatory protein expression in oxidized low-density lipoprotein-stimulated human vascular endothelial cells. J Cardiovasc Pharmacol.2011;57(6):721-7.
  187. 187..
    Zhou W,Chai H,Courson A,Lin PH,Lumsden AB,Yao Q, et al. Ginkgolide A attenuates homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg. 2006;44(4):853-62.
  188. 188..
    Maerz S,Liu CH,Guo W,Zhu YZ. Anti-ischaemic effects of bilobalide on neonatal rat cardiomyocytes and the involvement of the platelet-activating factor receptor. Biosci Rep. 2011;31(5):439-47.
  189. 189..
    Cho HJ,Nam KS. Inhibitory effect of ginkgolide B on platelet aggregation in a cAMP- and cGMP-dependent manner by activated MMP-9. J Biochem Mol Biol. 2007;40(5):678-83.
  190. 190..
    Cheung F,Siow YL,O K. Inhibition by ginkgolides and bilobalide of the production of nitric oxide in macrophages (THP-1) but not in endothe-lial cells (HUVEC). Biochem Pharmacol. 2001;61(4):503-10.
  191. 191..
    Priyanka A,Nisha VM,Anusree SS,Raghu KG. Bilobalide attenuates hypoxia induced oxidative stress, inflammation, and mitochondrial dysfunctions in 3T3-L1 adipocytes via its antioxidant potential. Free Radic Res. 2014;48(10):1206-17.
  192. 192..
    Lachachi H,Plantavid M,Simon MF,Chap H,Braquet P,Douste-Blazy L. Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021. Biochem Biophys Res Commun. 1985;132(2):460-6.
  193. 193..
    Lamant V,Mauco G,Braquet P,Chap H,Douste-Blazy L. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. Biochem Pharmacol.1987;36(17):2749-52.
  194. 194..
    Doi H,Sato K,Shindou H,Sumi K,Koyama H,Hosoya T, et al. Blood-brain barrier permeability of ginkgolide: comparison of the behavior of PET probes 7α- [18F] fluoro- and 10-O-p- [11C] methylbenzyl ginkgolide B in monkey and rat brains. Bioorg Med Chem. 2016;24(21):5148-57.
  195. 195..
    MacLennan KM,Darlington CL,Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 2002;67(3):235-57.
  196. 196..
    Hu L,Chen Z,Cheng X,Xie Y. Chemistry of ginkgolides: structure-activity relationship as PAF antagonists. Pure Appl Chem. 1999;71:1153-6.
  197. 197..
    Hu L,Chen Z,Xie Y,Jiang Y,Zhen H. Alkyl and alkoxycarbonyl derivatives of ginkgolide B: synthesis and biological evaluation of PAF inhibitory activity. Bioorg Med Chem. 2000;8(6):1515-21.
  198. 198..
    Xia SH,Hu CX,Zhao ZL,Xia GD,Di Y. Significance of platelet activating factor receptor expression in pancreatic tissues of rats with severe acute pancreatitis and effects of BN52021. World J Gastroenterol.2007;13(21):2992-8.
  199. 199..
    Kondratskaya EL,Pankratov YV,Lalo UV,Chatterjee SS,Krishtal OA. Inhibition of hippocampal LTP by ginkgolide B is mediated by its blocking action on PAF rather than glycine receptors. Neurochem Int.2004;44(3):171-7.
  200. 200..
    Montrucchio G,Bergerone S,Bussolino F,Alloatti G,Silvestro L,Lupia E, et al. Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Circulation. 1993;88(4 Pt 1):1476-83.
  201. 201..
    Chakrabarty S,Thomas P,Sheridan DJ. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischaemia. Eur Heart J.1991;12(5):583-9.
  202. 202..
    Wainwright CL,Parratt JR,Bigaud M. The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion. Eur Heart J. 1989;10(3):235-43.
  203. 203..
    Ye W,Wang J,Little PJ,Zou J,Zheng Z,Lu J, et al. Anti-atherosclerotic effects and molecular targets of ginkgolide B from Ginkgo biloba. Acta Pharm Sin B. 2024;14(1):1-19.
  204. 204..
    Vogensen SB,Strømgaard K,Shindou H,Jaracz S,Suehiro M,Ishii S, et al. Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003;46(4):601-8.
  205. 205..
    Strømgaard K,Saito DR,Shindou H,Ishii S,Shimizu T,Nakanishi K. Ginkgolide derivatives for photolabeling studies: preparation and pharmacological evaluation. J Med Chem. 2002;45(18):4038-46.
  206. 206..
    González-Núñez V,Bachert C,Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf.2016;15(10):1439-48.
  207. 207..
    Didamoony MA,Atwa AM,Ahmed LA. A novel mechanistic approach for the anti-fibrotic potential of rupatadine in rat liver via amendment of PAF/NF-κB p65/TGF-β1 and hedgehog/HIF-1α/VEGF trajectories. Inflammopharmacology. 2023;31(2):845-58.
  208. 208..
    Hsu HC,Yang WC,Tsai WJ,Chen CC,Huang HY,Tsai YC. Alphabulnesene, a novel PAF receptor antagonist isolated from Pogostemon cablin. Biochem Biophys Res Commun. 2006;345(3):1033-8.
  209. 209..
    Terashita Z,Tsushima S,Yoshioka Y,Nomura H,Inada Y,Nishikawa K. CV-3988: a specific antagonist of platelet activating factor (PAF). Life Sci. 1983;32(17):1975-82.
  210. 210..
    Valone FH. Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-noctadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). Biochem Biophys Res Commun. 1985;126(1):502-8.
  211. 211..
    Terashita Z,Imura Y,Takatani M,Tsushima S,Nishikawa K. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987;242(1):263-8.
  212. 212..
    Toyofuku T,Kubo K,Kobayashi T,Kusama S. Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep. Prostaglandins. 1986;31(2):271-81.
  213. 213..
    D’Humières S,Russo-Marie F,Vargaftig BB. PAF-acether-induced synthesis of prostacyclin by human endothelial cells. Eur J Pharmacol.1986;131(1):13-9.
  214. 214..
    Handley DA,Tomesch JC,Saunders RN. Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb Haemost. 1986;56(1):40-4.
  215. 215..
    Koltai M,Braquet PG. Platelet-activating factor antagonists. Clin Rev Allergy. 1994;12(4):361-80.
  216. 216..
    Merlos M,Gómez LA,Giral M,Vericat ML,García-Rafanell J,Forn J. Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents. Br J Pharmacol. 1991;104(4):990-4.
  217. 217..
    Wissner A,Carroll ML,Green KE,Kerwar SS,Pickett WC,Schaub RE, et al. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor. J Med Chem.1992;35(9):1650-62.
  218. 218..
    O’Hair DP,Roza AM,Komorowski R,Moore G,McManus RP,Johnson CP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993;7(1):79-84.
  219. 219..
    Handley DA,Van Valen RG,Melden MK,Houlihan WJ,Saunders RN. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. J Pharmacol Exp Ther.1988;247(2):617-23.
  220. 220..
    Kuitert LM,Angus RM,Barnes NC,Barnes PJ,Bone MF,Chung KF, et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med.1995;151(5):1331-5.
  221. 221..
    Kingsnorth AN,Galloway SW,Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995;82(10):1414-20.
  222. 222..
    Casals-Stenzel J,Heuer HO. Use of WEB 2086 and WEB 2170 as plateletactivating factor antagonists. Methods Enzymol. 1990;187:455-65.
  223. 223..
    Kornecki E,Ehrlich YH,Lenox RH. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzo-diazepines. Science. 1984;226(4681):1454-6.
  224. 224..
    Hwang SB,Lam MH,Biftu T,Beattie TR,Shen TY. Trans-2,5-Bis-(3,4,5-trimethoxyphenyl) tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. J Biol Chem.1985;260(29):15639-45.
  225. 225..
    Tsoupras AB,Papakyriakou A,Demopoulos CA,Philippopoulos AI. Synthesis, biochemical evaluation and molecular modeling studies of novel rhodium complexes with nanomolar activity against Platelet Activating Factor. J Inorg Biochem. 2013;120:63-73.
  226. 226..
    Sioriki E,Lordan R,Nahra F,van Hecke K,Zabetakis I,Nolan SP. In vitro anti-atherogenic properties of N-heterocyclic carbene aurate(I) compounds. ChemMedChem. 2018;13(23):2484-7.
  227. 227..
    Albert DH,Magoc TJ,Tapang P,Luo G,Morgan DW,Curtin M, et al. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist. Eur J Pharmacol. 1997;325(1):69-80.
  228. 228..
    Berdel WE. Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer. 1991;64(2):208-11.
  229. 229..
    Principe P,Sidoti C,Pignol B,Coulomb H,Mencia-Huerta JM,Broquet C,et al. Alkyl lysophospholipids in cancer treatment: their cytostatic and immunomodulatory role. In: Nigam S, Honn KV, Marnett LJ, Walden TL, editors. Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury, In: Proceedings of the 2nd International Conference September 17-21, 1991 Berlin, FRG. Boston, MA: Springer US;1993. p. 741-8.
  230. 230..
    Noseda A,Godwin PL,Modest EJ. Effects of antineoplastic ether lipids on model and biological membranes. Biochim Biophys Acta.1988;945(1):92-100.
  231. 231..
    van Blitterswijk WJ,Hilkmann H,Storme GA. Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion. Lipids. 1987;22(11):820-3.
  232. 232..
    Diomede L,Principe P,Domingo M,Broquet C,Chabrier P,Braquet P, et al. Effect of paf antagonists on the cytotoxic activity of antineoplastic ether phospholipids. Int J Oncol. 1993;2(5):777-80.
  233. 233..
    de Oliveira Neto XA,Alves ACS,Junior RAD,Rodrigues RP,Lancellotti M,Almeida WP, et al. Molecular docking reveals the binding modes of anticancer alkylphospholipids and lysophosphatidylcholine within the catalytic domain of cytidine triphosphate: phosphocholine cytidyltransferase. Eur J Lipid Sci Technol. 2020;122(7):1900422.
  234. 234..
    Nitulescu GM,Margina D,Juzenas P,Peng Q,Olaru OT,Saloustros E, et al. Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (review). Int J Oncol. 2016;48(3):869-85.
  235. 235..
    Munder PG,Westphal O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem Immunol. 1990;49:206-35.
  236. 236..
    van Blitterswijk WJ,Verheij M. Anticancer alkylphospholipids:mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des. 2008;14(21):2061-74.
  237. 237..
    Principe P,Sidoti C,Braquet P. Tumor cell kinetics following antineoplastic ether phospholipid treatment. Cancer Res. 1992;52(9):2509-15.
  238. 238..
    Andreesen R,Modolell M,Weltzien HU,Eibl H,Common HH,Löhr GW, et al. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res. 1978;38(11 Pt 1):3894-9.
  239. 239..
    Vogler WR,Olson AC,Okamoto S,Somberg LB,Glasser L. Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation. Lipids. 1987;22(11):919-24.
  240. 240..
    King MT,Eckhardt K,Gocke E,Wild D,Berdel WE,Munder PG. Failure to detect mutagenic effects of anti-tumor alkyl-lysophospholipids. Cancer Lett. 1981;12(3):217-22.
  241. 241..
    Bauchinger M,Dresp J,Schmid E,Berdel WE. Cytogenetic effects of an alkyl-lysophospholipid derivative in human peripheral lymphocytes exposed in vitro and in vivo. Mutat Res. 1983;121(3-4):225-31.
  242. 242..
    Alves A,Dias RA,Kagami LP,das Neves GM,Torres FC,Eifler-Lima VL, et al. Beyond the “Lock and Key” paradigm: targeting lipid rafts to induce the selective apoptosis of cancer cells. Curr Med Chem.2018;25(18):2082-104.
  243. 243..
    Boggs KP,Rock CO,Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP: phosphocholine cytidylyltransferase step. J Biol Chem.1995;270(13):7757-64.
  244. 244..
    Cui Z,Houweling M,Chen MH,Record M,Chap H,Vance DE, et al. A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. J Biol Chem. 1996;271(25):14668-71.
  245. 245..
    Zweigner J,Jackowski S,Smith SH,Van Der Merwe M,Weber JR,Tuomanen EI. Bacterial inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain. J Exp Med. 2004;200(1):99-106.
  246. 246..
    Wieder T,Orfanos CE,Geilen CC. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem. 1998;273(18):11025-31.
  247. 247..
    Boggs K,Rock CO,Jackowski S. The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. Biochim Biophys Acta. 1998;1389(1):1-12.
  248. 248..
    van der Luit AH,Budde M,Ruurs P,Verheij M,van Blitterswijk WJ. Alkyllysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem. 2002;277(42):39541-7.
  249. 249..
    Van Der Luit AH,Budde M,Verheij M,Van Blitterswijk WJ. Different modes of internalization of apoptotic alkyl-lysophospholipid and cellrescuing lysophosphatidylcholine. Biochem J. 2003;374(Pt 3):747-53.
  250. 250..
    Vogler WR,Shoji M,Hayzer DJ,Xie Y,Renshaw M. The effect of edelfosine on CTP: cholinephosphate cytidylyltransferase activity in leukemic cell lines. Leuk Res. 1996;20(11-12):947-51.
  251. 251..
    Cornell RB,Ridgway ND. CTP:phosphocholine cytidylyltransferase: function, regulation, and structure of an amphitropic enzyme required for membrane biogenesis. Prog Lipid Res. 2015;59:147-71.
  252. 252..
    Lykidis A,Jackson P,Jackowski S. Lipid activation of CTP: phosphocholine cytidylyltransferase alpha: characterization and identification of a second activation domain. Biochemistry. 2001;40(2):494-503.
  253. 253..
    Menendez JA,Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-77.
  254. 254..
    Swinnen JV,Van Veldhoven PP,Timmermans L,De Schrijver E,Brusselmans K,Vanderhoydonc F, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun. 2003;302(4):898-903.
  255. 255..
    Ramírez de Molina A,Báñez-Coronel M,Gutiérrez R,Rodríguez-González A,Olmeda D,Megías D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res.2004;64(18):6732-9.
  256. 256..
    Ramírez de Molina A,Gallego-Ortega D,Sarmentero-Estrada J,Lagares D,Gómez Del Pulgar T,Bandrés E, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol. 2008;40(9):1753-63.
  257. 257..
    Blank ML,Lee T,Fitzgerald V,Snyder F. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem. 1981;256(1):175-8.
  258. 258..
    Lee TC,Malone B,Blank ML,Fitzgerald V,Snyder F. Regulation of the synthesis of platelet-activating factor and its inactive storage precursor (1-alkyl-2-acyl-sn-glycero-3-phosphocholine) from 1-alkyl-2-acetyl-snglycerol by rabbit platelets. J Biol Chem. 1990;265(16):9181-7.
  259. 259..
    Tarui M,Shindou H,Kumagai K,Morimoto R,Harayama T,Hashidate T, et al. Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2. J Lipid Res. 2014;55(7):1386-96.
  260. 260..
    Debela DT,Muzazu SG,Heraro KD,Ndalama MT,Mesele BW,Haile DC, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034370.
  261. 261..
    Knight SR,Shaw CA,Pius R,Drake TM,Norman L,Ademuyiwa AO,Adisa AO,Aguilera ML,Al-Saqqa SW,Al-Slaibi I,Bhangu A. Global variation in postoperative mortality and complications after cancer surgery:a multicentre, prospective cohort study in 82 countries. Lancet.2021;397(10272):387-97.
  262. 262..
    Roy A,Li SD. Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol.2016;8(6):891-908.
  263. 263..
    Yang MH,Ha IJ,Lee SG,Um JY,Ahn KS. Abrogation of STAT3 activation cascade by Ginkgolide C mitigates tumourigenesis in lung cancer preclinical model. J Pharm Pharmacol. 2021;73(12):1630-42.
  264. 264..
    Yun HJ,Jeoung DJ,Jin S,Park JH,Lee EW,Lee HT, et al. Induction of cell cycle arrest, apoptosis, and reducing the expression of MCM proteins in human lung carcinoma A549 cells by cedrol, isolated from Juniperus chinensis. J Microbiol Biotechnol. 2022;32(7):918-26.
  265. 265..
    Zhang SY,Li XB,Hou SG,Sun Y,Shi YR,Lin SS. Cedrol induces autophagy and apoptotic cell death in A549 non-small cell lung carcinoma cells through the P13K/Akt signaling pathway, the loss of mitochondrial transmembrane potential and the generation of ROS. Int J Mol Med.2016;38(1):291-9.
  266. 266..
    Wang XR,Jiang ZB,Xu C,Meng WY,Liu P,Zhang YZ, et al. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacol Res. 2022;179:106198.
  267. 267..
    Yang MH,Ha IJ,Lee SG,Lee J,Um JY,Ahn KS. Ginkgolide C promotes apoptosis and abrogates metastasis of colorectal carcinoma cells by targeting Wnt/β-catenin signaling pathway. IUBMB Life.2021;73(10):1222-34.
  268. 268..
    Sun L,He Z,Ke J,Li S,Wu X,Lian L, et al. PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer. Int J Clin Exp Pathol. 2015;8(1):432-40.
  269. 269..
    Khan I,Mahfooz S,Saeed M,Ahmad I,Ansari IA. Andrographolide inhibits proliferation of colon cancer SW-480 cells via downregulating Notch signaling pathway. Anticancer Agents Med Chem. 2021;21(4):487-97.
  270. 270..
    Khan I,Mahfooz S,Faisal M,Alatar AA,Ansari IA. Andrographolide induces apoptosis and cell cycle arrest through inhibition of aberrant hedgehog signaling pathway in colon cancer cells. Nutr Cancer.2021;73(11-12):2428-46.
  271. 271..
    Khan I,Khan F,Farooqui A,Ansari IA. Andrographolide exhibits anticancer potential against human colon cancer cells by inducing cell cycle arrest and programmed cell death via augmentation of intracellular reactive oxygen species level. Nutr Cancer. 2018;70(5):787-803.
  272. 272..
    Zhang R,Zhao J,Xu J,Jiao DX,Wang J,Gong ZQ, et al. Andrographolide suppresses proliferation of human colon cancer SW620 cells through the TLR4/NF-κB/MMP-9 signaling pathway. Oncol Lett.2017;14(4):4305-10.
  273. 273..
    Yuan M,Meng W,Liao W,Lian S. Andrographolide antagonizes TNF-α-induced IL-8 via inhibition of NADPH oxidase/ROS/NF-κB and Src/MAPKs/AP-1 axis in human colorectal cancer HCT116 cells. J Agric Food Chem. 2018;66(20):5139-48.
  274. 274..
    Yadav RP,Sadhukhan S,Saha ML,Ghosh S,Das M. Exploring the mechanism of andrographolide in the treatment of gastric cancer through network pharmacology and molecular docking. Sci Rep.2022;12(1):18413.
  275. 275..
    Dai L,Wang G,Pan W. Andrographolide inhibits proliferation and metastasis of SGC7901 gastric cancer cells. Biomed Res Int.2017;2017:6242103.
  276. 276..
    Lim SC,Jeon HJ,Kee KH,Lee MJ,Hong R,Han SI. Andrographolide induces apoptotic and non-apoptotic death and enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in gastric cancer cells. Oncol Lett. 2017;13(5):3837-44.
  277. 277..
    Jiang W,Cong Q,Wang Y,Ye B,Xu C. Ginkgo may sensitize ovarian cancer cells to cisplatin: antiproliferative and apoptosis-inducing effects of ginkgolide B on ovarian cancer cells. Integr Cancer Ther.2014;13(3):NP10-7.
  278. 278..
    Chou YJ,Lin CC,Hsu YC,Syu JL,Tseng LM,Chiu JH, et al. Andrographolide suppresses the malignancy of triple-negative breast cancer by reducing THOC1-promoted cancer stem cell characteristics. Biochem Pharmacol. 2022;206:115327.
  279. 279..
    Tohkayomatee R,Reabroi S,Tungmunnithum D,Parichatikanond W,Pinthong D. Andrographolide exhibits anticancer activity against breast cancer cells (MCF-7 and MDA-MB-231 cells) through suppressing cell proliferation and inducing cell apoptosis via inactivation of ER-α receptor and PI3K/AKT/mTOR signaling. Molecules. 2022;27(11):3544.
  280. 280..
    Banerjee M,Chattopadhyay S,Choudhuri T,Bera R,Kumar S,Chakraborty B, et al. Cytotoxicity and cell cycle arrest induced by andrographolide lead to programmed cell death of MDA-MB-231 breast cancer cell line. J Biomed Sci. 2016;23:40.
  281. 281..
    Zhai Z,Qu X,Li H,Ouyang Z,Yan W,Liu G, et al. Inhibition of MDAMB-231 breast cancer cell migration and invasion activity by andrographolide via suppression of nuclear factor-κB-dependent matrix metalloproteinase-9 expression. Mol Med Rep. 2015;11(2):1139-45.
  282. 282..
    Zhi Y,Pan J,Shen W,He P,Zheng J,Zhou X, et al. Ginkgolide B inhibits human bladder cancer cell migration and invasion through microRNA-223-3p. Cell Physiol Biochem. 2016;39(5):1787-94.
  283. 283..
    Xuan L,Hu JH,Bi R,Liu SQ,Wang CX. Andrographolide inhibits proliferation and promotes apoptosis in bladder cancer cells by interfering with NF- κ B and PI3K/AKT signaling in vitro and in vivo. Chin J Integr Med.2022;28(4):349-56.
  284. 284..
    Forestier-Román IS,López-Rivas A,Sánchez-Vázquez MM,Rohena-Rivera K,Nieves-Burgos G,Ortiz-Zuazaga H, et al. Andrographolide induces DNA damage in prostate cancer cells. Oncotarget.2019;10(10):1085-101.
  285. 285..
    Mir H,Kapur N,Singh R,Sonpavde G,JrLillard JW,Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016;15(6):819-26.
  286. 286..
    Othman NS,Mohd Azman DK. Andrographolide induces G2/M cell cycle arrest and apoptosis in human glioblastoma DBTRG-05MG cell line via ERK1/2 /c-Myc/p53 signaling pathway. Molecules.2022;27(19):6686.
  287. 287..
    Chang KF,Huang XF,Chang JT,Huang YC,Weng JC,Tsai NM. Cedrol suppresses glioblastoma progression by triggering DNA damage and blocking nuclear translocation of the androgen receptor. Cancer Lett.2020;495:180-90.
  288. 288..
    Yang MH,Baek SH,Um JY,Ahn KS. Anti-neoplastic effect of ginkgolide C through modulating c-Met phosphorylation in hepatocellular carcinoma cells. Int J Mol Sci. 2020;21(21):8303.
  289. 289..
    Yang W,Zhao J,Wang Y,Xu H,Wu Z,Hu Y, et al. In vivo inhibitory activity of andrographolide derivative ADN-9 against liver cancer and its mechanisms involved in inhibition of tumor angiogenesis. Toxicol Appl Pharmacol. 2017;327:1-12.
  290. 290..
    Duitman J,Hartl L,Roelofs J,Bijlsma MF,Spek CA. Non-tumor CCAAT/enhancer-binding protein delta potentiates tumor cell extravasation and pancreatic cancer metastasis formation. Biomolecules.2021;11(8):1079.
  291. 291..
    Lou C,Lu H,Ma Z,Liu C,Zhang Y. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-κB pathway. Biomed Pharmacother. 2019;109:563-72.
  292. 292..
    Lin X,Kong D,Chen ZS. Editorial: chemo-radiation-resistance in cancer therapy. Front Pharmacol. 2022;13:904063.
  293. 293..
    Vikram B,Coleman CN,Deye JA. Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources. Oncology. 2009;23(3):279-83.
  294. 294..
    Chen GZ,Zhu HC,Dai WS,Zeng XN,Luo JH,Sun XC. The mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivity. J Thorac Dis. 2017;9(3):849-59.
  295. 295..
    Wu TS,Lin BR,Chang HH,Chang CC. Radio resistance mechanisms of cancers: an overview and future perspectives. Biol Med. 2015;2015:1-7.
  296. 296..
    Ling R,Wang J,Fang Y,Yu Y,Su Y,Sun W, et al. HDAC-an important target for improving tumor radiotherapy resistance. Front Oncol.2023;13:1193637.
  297. 297..
    Cheng J,Tian L,Ma J,Gong Y,Zhang Z,Chen Z, et al. Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma. Mol Oncol. 2015;9(1):105-14.
  298. 298..
    Zhou Q,Yao X,Wu C,Chen S,Fan D. Knockdown of ubiquitin-specific protease 53 enhances the radiosensitivity of human cervical squamous cell carcinoma by regulating DNA damage-binding protein 2. Technol Cancer Res Treat. 2020;19:1533033820929792.
  299. 299..
    Zimmerman MA,Huang Q,Li F,Liu X,Li CY. Cell death-stimulated cell proliferation: a tissue regeneration mechanism usurped by tumors during radiotherapy. Semin Radiat Oncol. 2013;23(4):288-95.
  300. 300..
    Tominaga H,Kodama S,Matsuda N,Suzuki K,Watanabe M. Involvement of reactive oxygen species (ROS) in the induction of genetic instability by radiation. J Radiat Res. 2004;45(2):181-8.
  301. 301..
    Yamamori T,Yasui H,Yamazumi M,Wada Y,Nakamura Y,Nakamura H, et al. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic Biol Med. 2012;53(2):260-70.
  302. 302..
    Sahu RP,Petrache I,Van Demark MJ,Rashid BM,Ocana JA,Tang Y, et al. Cigarette smoke exposure inhibits contact hypersensitivity via the generation of platelet-activating factor agonists. J Immunol.2013;190(5):2447-54.
  303. 303..
    Patel KD,Zimmerman GA,Prescott SM,McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem. 1992;267(21):15168-75.
  304. 304..
    Konger RL,Marathe GK,Yao Y,Zhang Q,Travers JB. Oxidized glycerophosphocholines as biologically active mediators for ultraviolet radiation-mediated effects. Prostaglandins Other Lipid Med.2008;87(1-4):1-8.
  305. 305..
    Yao B,Liu B,Shi L,Li X,Ren C,Cai M, et al. PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells. Oncotarget. 2017;8(8):13846-54.
  306. 306..
    Yang R,Niepel M,Mitchison TK,Sorger PK. Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin Pharmacol Ther. 2010;88(1):34-8.
  307. 307..
    Hug H,Strand S,Grambihler A,Galle J,Hack V,Stremmel W, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem.1997;272(45):28191-3.
  308. 308..
    Jin SM,Cho HJ,Jung ES,Shim MY,Mook-Jung I. DNA damage-inducing agents elicit gamma-secretase activation mediated by oxidative stress. Cell Death Differ. 2008;15(9):1375-84.
  309. 309..
    Li T,Southall MD,Yi Q,Pei Y,Lewis D,Al-Hassani M, et al. The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines. J Biol Chem.2003;278(19):16614-21.
  310. 310..
    Darst M,Al-Hassani M,Li T,Yi Q,Travers JM,Lewis DA, et al. Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line. J Immunol. 2004;172(10):6330-5.
  311. 311..
    Grottke C,Mantwill K,Dietel M,Schadendorf D,Lage H. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer.2000;88(4):535-46.
  312. 312..
    Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004;3(4):294-300.
  313. 313..
    Qu K,Lin T,Wang Z,Liu S,Chang H,Xu X, et al. Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma. Front Med. 2014;8(2):227-35.
  314. 314..
    Sahu RP,Ferracini M,Travers JB. Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists. Med Inflamm.2015;2015:820543.
  315. 315..
    Heon Seo K,Ko HM,Kim HA,Choi JH,Jun Park S,Kim KJ, et al. Plateletactivating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation. Cancer Res. 2006;66(9):4681-6.
  316. 316..
    Onuchic AC,Machado CML,Saito RF,Rios FJ,Jancar S,Chammas R. Expression of PAFR as part of a prosurvival response to chemotherapy:a novel target for combination therapy in melanoma. Med Inflamm.2012;2012:175408.
  317. 317..
    Yu Y,Zhang X,Hong S,Zhang M,Cai Q,Zhang M, et al. The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy. Br J Cancer. 2014;111(3):515-24.
  318. 318..
    Kawasaki K,Kasamatsu A,Ando T,Saito T,Nobuchi T,Nozaki R, et al. Ginkgolide B regulates CDDP chemoresistance in oral cancer via the platelet-activating factor receptor pathway. Cancers. 2021;13(24):6299.

Leia o texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website